Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Type I interferons (IFNs) exhibit anti-cancer properties during tumor progression.
• Tumor cells possess mechanisms to evade immune-mediated inhibition, but these are not fully understood.
• Glioma stem-like cells (GSCs) are implicated in brain tumor growth and resistance.

Purpose of the Study:

• To elucidate the molecular mechanisms by which GSCs evade type I IFN-mediated immune suppression.
• To identify key regulators involved in GSC survival and tumor initiation under immune pressure.

Main Methods:

• Investigated STAT1 signaling pathways in GSCs.
• Utilized epigenetic analysis to identify regulators of STAT1 expression.
• Employed gene manipulation (overexpression/depletion) and assessed GSC proliferation and tumor growth in vivo.

Main Results:

• GSCs evade type I IFN suppression by downregulating STAT1 expression.
• MBD3, an epigenetic regulator, mediates STAT1 downregulation in GSCs by recruiting the NuRD complex to the STAT1 promoter.
• STAT1 re-expression or MBD3 inhibition led to p21 induction, GSC resensitization to IFN, reduced tumor growth, and improved survival in animal models.

Conclusions:

• MBD3-mediated inactivation of STAT1 signaling confers a survival advantage to GSCs, enabling them to escape type I IFN-induced suppression.
• Targeting MBD3 represents a potential therapeutic strategy to overcome GSC immune evasion and reduce tumorigenic potential.